IPSC-CMs
Forecast New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- Not on record
- Points of contact
-
- NCTR Acquisition Liaison nctracquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is procuring induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for in vitro research, with solicitation release targeted for May 1, 2027 and award expected June 1, 2027. The procurement carries no set-aside designation.
Estimated award value ranges from $25,000 to $250,000. Questions and inquiries should be directed to the FDA Acquisition Liaison at nctracquisitions@fda.hhs.gov.
Forecast text
Purchase of iPSC-CMs for in-vitro research
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast